Higher radiation dose on immune cells is associated with radiation-induced lymphopenia and worse prognosis in patients with locally advanced esophageal squamous cell carcinoma

被引:3
|
作者
Qiu, Jianjian [1 ]
Lin, Hancui [1 ]
Ke, Dongmei [1 ]
Yu, Yilin [1 ]
Xu, Jiaying [1 ]
Qiu, Hejin [1 ]
Zheng, Qunhao [1 ]
Li, Hui [1 ]
Zheng, Hongying [1 ]
Liu, Lingyun [1 ]
Wang, Zhiping [1 ]
Yao, Qiwei [1 ]
Li, Jiancheng [1 ]
机构
[1] Fujian Med Univ, Fujian Canc Hosp, Clin Oncol Sch, Fuzhou, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
effective dose to immune cells (EDIC); esophageal carcinoma; radiation-induced lymphopenia (RIL); prognosis; radiotherapy; LYMPHOCYTE NADIR; OPEN-LABEL; CANCER; SURVIVAL; CHEMORADIATION; RADIOTHERAPY; NIVOLUMAB; IMPACT; PEMBROLIZUMAB; MULTICENTER;
D O I
10.3389/fimmu.2023.1066255
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
BackgroundTo explore the effective dose to immune cells (EDIC) for better prognosis while avoiding radiation-induced lymphopenia (RIL) in patients with locally advanced esophageal squamous cell carcinoma (ESCC). Materials and methodsOverall, 381 patients with locally advanced ESCC receiving definitive radiotherapy with or without chemotherapy (dRT +/- CT) between 2014 and 2020 were included in this study. The EDIC model was calculated by radiation fraction number and mean doses to the heart, lung, and integral body. The correlation between EDIC and clinical outcomes was analyzed using Cox proportional hazards regression, and risk factors for RIL were determined by logistic regression analysis. ResultsThe median EDIC was 4.38 Gy. Multivariate analysis revealed that low-EDIC significantly improved the OS of patients when compared with high-EDIC (HR = 1.614, P = 0.003) and PFS (HR = 1.401, P = 0.022). Moreover, high-EDIC was associated with a higher incidence of grade 4 RIL (OR = 2.053, P = 0.007) than low-EDIC. In addition, we identified body mass index (BMI), tumor thickness, and nodal stage as independent prognostic factors of OS and PFS, while BMI (OR = 0.576, P = 0.046) and weight loss (OR = 2.214, P = 0.005) as independent risk factors of grade 4 RIL. In subgroup analyses, the good group had better clinical outcomes than the remaining two groups (P< 0.001). ConclusionThis study demonstrated that EDIC significantly correlates with poor clinical outcomes and severe RIL. Optimizing treatment plans to decrease the radiation doses to immune cells is critical for improving the outcomes.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Long-term clinical outcome of intensity-modulated radiation therapy for locally advanced esophageal squamous cell carcinoma
    Ge, Xiaolin
    Yang, Xi
    Lu, Xiaohu
    Wen, Wei
    Zhen, Fuxi
    Ye, Hongxun
    Zhu, Hongcheng
    Cao, Yuandong
    Zhang, Sheng
    Cheng, Hongyan
    Ma, Jianxin
    Yang, Baixia
    Dai, Shengbin
    Guo, Qing
    Cai, Jing
    Sun, Xinchen
    TUMORI JOURNAL, 2015, 101 (02): : 168 - 173
  • [32] Radiation-Induced Oropharyngeal Squamous Cell Carcinoma: Case Report and Review of the Literature
    Giannini, Lorenzo
    Alliata, Andrea
    Cristofaro, Valentina
    Incandela, Fabiola
    Pompilio, Madia
    Ottini, Arianna
    Cavalieri, Stefano
    Nuzzolese, Imperia
    Iacovelli, Nicola Alessandro
    Franceschini, Marzia
    Deganello, Alberto
    CURRENT ONCOLOGY, 2023, 30 (07) : 6708 - 6719
  • [33] Optimizing neoadjuvant radiotherapy for locally advanced esophageal squamous cell carcinoma: a comprehensive review on the role of concomitant or sequential immune checkpoint inhibitors
    Ghalehtaki, Reza
    Amini, Arya
    Abyaneh, Romina
    ESOPHAGUS, 2025, 22 (01) : 5 - 18
  • [34] The Impact of Radiotherapy Dose in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy
    Lo, Chien-Ming
    Wang, Yu-Ming
    Chen, Yen-Hao
    Fang, Fu-Min
    Huang, Shun-Chen
    Lu, Hung-, I
    Li, Shau-Hsuan
    CURRENT ONCOLOGY, 2021, 28 (02) : 1354 - 1365
  • [35] Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
    Zeng, J.
    Cui, X.
    Cheng, L.
    Chen, Y.
    Du, X.
    Sheng, L.
    CANCER RADIOTHERAPIE, 2021, 25 (05): : 441 - 446
  • [36] Combined modality therapy for patients with esophageal squamous cell carcinoma: Radiation dose and survival analyses
    Shueng, Pei-Wei
    Huang, Chun-Chieh
    Liu, Yu-Ming
    Wu, Yuan-Hong
    Huang, Pin-, I
    Yen, Sang-Hue
    Lin, Kuan-Heng
    Hsu, Chen-Xiong
    THORACIC CANCER, 2023, 14 (02) : 143 - 148
  • [37] Combining the systemic inflammation response index and prognostic nutritional index to predict the prognosis of locally advanced elderly esophageal squamous cell carcinoma patients undergoing definitive radiotherapy
    Yan, Ke
    Wei, Wanyi
    Shen, Wenbin
    Du, Xingyu
    Zhu, Shuchai
    Zhao, Hanjun
    Wang, Xiaobin
    Yang, Jie
    Zhang, Xueyuan
    Deng, Wenzhao
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (01) : 13 - 25
  • [38] Post-radiation circulating tumor DNA as a prognostic factor in locally advanced esophageal squamous cell carcinoma
    Jia, Ru
    Zhao, Chuan-Hua
    Li, Pan-Song
    Liu, Rong-Rui
    Zhang, Yun
    Chen, Hai-E
    Chang, Lian-Peng
    Gong, Yu-Hua
    Guan, Yan-Fang
    Yi, Xin
    Xu, Jian-Ming
    ONCOLOGY LETTERS, 2021, 21 (01)
  • [39] Pirfenidone for the prevention of radiation-induced lung injury in patients with locally advanced oesophageal squamous cell carcinoma: a protocol for a randomised controlled trial
    Chen, Cheng
    Zeng, Bangwei
    Xue, Dan
    Cao, Rongxiang
    Liao, Siqin
    Yang, Yong
    Li, Zhihua
    Kang, Mingqiang
    Chen, Chun
    Xu, Benhua
    BMJ OPEN, 2022, 12 (10):
  • [40] Real-world management and outcomes of older patients with locally advanced esophageal squamous cell carcinoma: a multicenter retrospective study
    Saito, Yuki
    Hamamoto, Yasuo
    Hirata, Kenro
    Yamasaki, Makoto
    Watanabe, Masaya
    Abe, Tetsuya
    Tsubosa, Yasuhiro
    Hamai, Yoichi
    Murakami, Kentaro
    Bamba, Takeo
    Yoshii, Takako
    Tsuda, Masahiro
    Watanabe, Masayuki
    Ueno, Masaki
    Kitagawa, Yuko
    BMC CANCER, 2023, 23 (01)